Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by University Hospital, Antwerp.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Antwerp
ClinicalTrials.gov Identifier:
NCT00497211
First received: July 4, 2007
Last updated: July 5, 2007
Last verified: July 2007
  Purpose

Large acute myocardial infarctions are the most frequent cause of subsequent systolic heart failure. Some evidence exists on the improvement after intracoronary administration of bone marrow cells in patients with a recente acute myocardial infarction. Although subgroup analyses suggest that patients with the largest myocardial infarctions have the largest increase in ejection fraction after intracoronary bone marrow administration, there is no published trial including only large myocardial infarctions. Therefor we sought to confirm the subgroup analyses by conducting a trial in only large first acute myocardial infarction patients.


Condition Intervention Phase
Myocardial Infarction
Procedure: Intracoronary mononuclear cell infusion
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University Hospital, Antwerp:

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥20 and <80 years old
  • Acute myocardial infarction >2 and <96 hours from start to reperfusion
  • Cumulative ST-segment elevation >6 mm on 12 lead ECG
  • No functional myocardial impairment outside the myocardial infarction region
  • Succesful PCI of infarct related coronary artery
  • Left ventricular ejection fraction <50% on ventriculography, echo or MRI
  • Accepted anticonceptive use during the study for women of childbearing potential
  • Written and signed informed consent

Exclusion Criteria:

  • CPR > 10 minuts or persistent cardiogenic shock
  • complete left bundle branch block without concordant ST-segment elevation
  • Need foor cardiac surgery (valvular, coronary or other)
  • Trombocytopenia, coagulation disorders or hematological disease
  • History or active malignancy
  • Life expectancy (apart from acute myocardial infarction) <5 years
  • Dialysis or severe kidney insufficiency (creatinin clearance <30ml/')
  • Severe liver insufficiency
  • Severe respiratory disease
  • Systemic inflammatory pathology (acute or chronic, apart from inflammation associated with myocardial infarction)
  • Symptomatic cerebral or periferal vascular disease
  • Prior myocardial infarction or prior myocardial dysfunction
  • Prior CABG or heart valve surgery
  • Pregnancy, pregnancy wish or lactation <1 month
  • Psychiatrical illness
  • Physical or psychological inability to adhere to the protocol
  • Participation in other not yet completed study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00497211

Contacts
Contact: Steven E Haine, MD 0032.3.821.42.81 steven.haine@uza.be
Contact: Myriam Michiels, Nurse 0032.3.821.33.04 Myriam.michiels@uza.be

Locations
Belgium
Universitair Ziekenhuis Antwerpen Recruiting
Edegem, Belgium, 2650
Sub-Investigator: Johan Bosmans, MD, PhD         
Sub-Investigator: Marc Claeys, MD, PhD         
Sub-Investigator: Hielko Miljoen, MD, PhD         
Sponsors and Collaborators
University Hospital, Antwerp
Investigators
Principal Investigator: Steven E Haine, MD UZ Antwerpen
Study Director: Chris Vrints, MD, PhD UZ Antwerpen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00497211     History of Changes
Other Study ID Numbers: EC 3/39/123
Study First Received: July 4, 2007
Last Updated: July 5, 2007
Health Authority: Belgium: Institutional Review Board

Keywords provided by University Hospital, Antwerp:
First large acute myocardial infarction

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Cardiovascular Diseases
Heart Diseases
Ischemia
Myocardial Ischemia
Necrosis
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014